Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff
  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

Pediatr Infect Dis J 2013 Oct;32(10):1144-6

Potential for Palivizumab Interference with Commercially Available Antibody-Antigen Based Respiratory Syncytial Virus Diagnostic Assays.

Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA

Abstract

Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in infants. The potential for palivizumab to interfere with commercially available RSV diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.

Category: Journal Article
PubMed ID: #23584584 DOI: 10.1097/INF.0b013e31829561dd
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2013-04-16 Entry Last Modified: 2013-11-02
Feedback
-
-